Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02175394
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo solutionDevice: RespimatDevice: Handihaler
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 202
- Registration Number
- NCT02175342
Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- Drug: PlaceboDrug: Medium dose of Micardis®Drug: Low dose of Micardis®Drug: High dose of Micardis®
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1039
- Registration Number
- NCT02175355
Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02173678
Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo inhalation aerosolDrug: Placebo inhalation powder capsules
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 584
- Registration Number
- NCT02173691
BIBR 953 ZW in Healthy Elderly Subjects
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02173730
Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02173717
Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Striverdi® Respimat®
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1845
- Registration Number
- NCT02173769
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site 2, Ahaus, Germany
🇩🇪Boehringer Ingelheim Investigational Site 11, Aßlar, Germany
🇩🇪Boehringer Ingelheim Investigational Site 78, Bonn, Germany
Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic ObstructiveAsthma
- Interventions
- Drug: Berodual® Respimat®
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 245
- Registration Number
- NCT02173795
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: BI 1356 BS - TabletDrug: BI 1356 BS - Powder in bottle (PIB)
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT02173665